title: Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans.
abstract: Cilostazol, a novel cyclic adenosine monophosphate phosphodiesterase type III inhibitor, has been developed as an antiplatelet drug with a vasodilating action on peripheral arteries. The present study was designed to test, in humans, whether cilostazol can dilate the epicardial coronary arteries and what are its hemodynamic effects. Eight patients with chest pain syndrome were subjected to serial quantitative coronary arteriography immediately before and at 30, 60 and 150min after a single oral dose of cilostazol (200mg). Luminal cross-sectional areas (mm2) at the proximal and distal sites of major coronary arteries (6 segments at each sampling time) were significantly increased at 150 min after taking the drug. The percent increases relative to the baseline values were 25+/-7 (6.8+/-0.8-->8.3+/-1.0*) and 42+/-7% (2.1+/-0.3-->3.0+/-0.4*) in the right coronary artery, 24+/-5 (5.1+/-0.7-->6.1+/-0.8*) and 28+/-10% (1.6+/-0.31-->9+/-0.3*) in the left anterior descending artery, and 14+/-6 (5.9+/-0.9-->6.6+/-0.9*) and 24+/-10% (1.3+/-0.2-->1.5+/-0.2*) in the left circumflex artery, respectively (*p<0.05 vs baseline). This action, relative to that of nitroglycerine, was between 27% and 54%. Moreover, small but sustained decreases in systolic pulmonary pressure and stroke work index were observed. Thus, cilostazol has a mild coronary vasodilating action with minimal hemodynamic effects, thereby giving it a possible role in the treatment of coronary artery disease.
authors.affiliation: The First Department of Medicine, Nippon Medical School, Tokyo, Japan. FF9M-YSTK@asahi-net.or.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yasutake
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kunimi
authors.forename: Naoki
authors.initials: N
authors.lastname: Sato
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Yoshimichi
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Kusama
authors.forename: Noritake
authors.initials: N
authors.lastname: Hata
authors.forename: Morimasa
authors.initials: M
authors.lastname: Takayama
authors.forename: Kazuo
authors.initials: K
authors.lastname: Munakata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kishida
authors.forename: Teruo
authors.initials: T
authors.lastname: Takano
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Hayakawa
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002637:Chest Pain / Q000503:physiopathology; D000077407:Cilostazol; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000187:drug effects*; D004341:Drug Evaluation; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D013777:Tetrazoles / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D014664:Vasodilation / Q000187:drug effects
chemical_list: D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol